Granules India Q2 FY27: PAT Surges 39% YoY to ₹182 Cr, Margin Just Shy of Guided Band
PAT +39.23% YoY · revenue +20.28% · margins expanding · beat vs street
₹1,559.97 Cr
+20.28% YoY
₹181.84 Cr
+39.23% YoY
11.58%
+1.5pp YoY
₹7.22
Granules India's consolidated revenue crossed ₹1,500 Cr for the first time in Q2 FY27, at ₹1,559.97 Cr — up 20.3% YoY and 5.6% QoQ, matching the 20% YoY growth management cited in its own press release. Consolidated PAT of ₹181.84 Cr grew 39.2% YoY, well ahead of revenue growth, though it was almost flat QoQ (+1.0%) after a strong Q1. Standalone PAT was ₹108.52 Cr on revenue of ₹947.82 Cr (EPS ₹4.31); consolidated basic EPS came in at ₹7.22, down marginally from ₹7.26 in Q1 despite higher profit, because the company allotted 2.49 Cr new equity shares this quarter on warrant conversion, diluting the base.
Q2 FY-2027 vs prior quarters
EBITDA was ₹337.6 Cr, a 21.64% margin — up from 21.45% a year ago (margin expansion YoY) but down from 22.95% in Q1, and below the 22-23% band management had guided to sustain through FY27. Net profit margin shows the same pattern: 11.66% versus 10.08% YoY, but down from 12.17% QoQ. Management's own framing attributes the squeeze to "higher input and logistics costs from tensions in West Asia," and flags that "cost pressures will persist" while the company works with customers to pass them through "with a lag" — so the FY27 margin guidance is running behind plan this quarter rather than abandoned. No exceptional items hit Q2 FY27 or the year-ago quarter, so both the revenue and profit growth above are on a clean, comparable base.
The stock went into the print at ₹820.7, down 3.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional items this quarter (unlike H1 FY26's ~₹25.9 Cr Senn Chemicals acquisition cost), so growth is on a clean like-for-like base
FY27 capex ₹600 Cr (₹89 Cr spent Q1); EBITDA margins 22-23% expected to continue; peptide CDMO target PAT positive on annual basis FY27; 9 approvals from GGP pending FDA clearance of Gagillapur facility; FY27 growth continues (specific number deferred).
— This quarter: missed
Our pre-result preview had set the on-plan bar at ₹1,420-1,500 Cr revenue, 22-23% EBITDA margin and double-digit PAT growth, built on consensus that was 87.5% Buy-rated (median target ₹765) and a Q1 that had already beaten Motilal Oswal's revenue/EBITDA/PAT estimates. Actual revenue (₹1,559.97 Cr) and PAT growth (39.2%) both beat that range; margin alone missed, landing below the bottom of the guided band. On the pipeline side, management says it filed two more potential first-to-file ANDAs in H1 FY27 (three total), continuing the stated shift to complex generics and peptide CDMO — a business the prior concall had targeted for annual PAT breakeven in FY27, though this filing discloses no segment-level CDMO numbers to verify that independently. The quarter also carried two other threads from the event record: the Gagillapur facility underwent a fresh USFDA inspection that concluded October 30, 2026 (closing out a February 2025 warning letter tied to an August-September 2024 inspection, per the auditor's notes), and the promoter group completed its warrant-to-equity conversion (2.49 Cr shares, ₹1,096.1 Mn), which management says leaves the group with ₹828 Cr of net cash; two new wholly-owned subsidiaries were also incorporated during the quarter (Brazil and, just after quarter-end, Mexico).
W1
H2 FY27 EBITDA margin recovery toward the 22-23% guided band, given management's own warning that cost pressures will persist
W2
Peptide CDMO segment progress toward the FY27 annual PAT-breakeven target flagged last concall — no segment numbers disclosed this quarter
W3
Any further USFDA correspondence on Gagillapur following the October 30, 2026 inspection, relevant to the 9 pending GGP approvals flagged last quarter
Informational and educational content only. Not investment advice.